Company Overview
IceCure Medical Ltd operates as a commercial-stage medical device company focused on the research, development, and marketing of cryoablation systems, disposables, and technologies designed to treat tumors across the United States, Japan, India, China, Israel, and international markets. The firm functions within the broader healthcare sector, specifically targeting the medical devices industry, where it aims to advance therapeutic solutions for oncological applications. With a market capitalization of $27.43M, an annual revenue of $3.38M, and an employee count of 67, the company maintains a small-cap profile that reflects its early-to-mid stage of commercialization. These valuation and revenue figures indicate that the company is a micro-cap entity with limited market penetration, suggesting it is still in the process of scaling its operations and establishing a significant foothold in the global cryoablation market.
Financial Health
The company reported revenue of $3.38M for the trailing twelve months, accompanied by a net income of $-15,057,000 and an EBITDA of $-14,799,000, highlighting a substantial gap between top-line growth and bottom-line profitability that points to high operating costs or significant R&D expenditures relative to current sales. Free cash flow stands at $-8,915,750, which indicates that the company is currently burning cash to fund its growth initiatives and development efforts rather than generating surplus liquidity for immediate deployment. The gross margin is 36.3%, suggesting that the company retains a moderate portion of revenue after direct costs, though the operating margin of -329.6% reveals that general and administrative expenses or research costs are significantly outpacing gross profits. Furthermore, the profit margin of 0.0% confirms that the company has not yet achieved net profitability on a percentage basis despite generating revenue. Regarding balance sheet leverage, the company holds $8.90M in cash against $217,000 in debt, resulting in a debt-to-equity ratio of 2.40, which suggests a leveraged position where equity is the primary source of capitalization despite the low absolute debt level. The current ratio of 2.61 demonstrates strong short-term liquidity, indicating that the company possesses more than enough current assets to cover its short-term liabilities. Return on equity is -188.8% and return on assets is -71.3%, metrics that reveal management is currently utilizing the company's capital base to generate losses rather than positive returns, a common characteristic of pre-profitability growth-stage biotech or medical device firms.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is -4.16, implying that the market is pricing in future earnings expectations that are not yet realized in the current period. The price-to-book ratio stands at 3.02, indicating that the market values the company at more than three times its book value, which suggests a premium placed on the company's intellectual property, potential future market share, or growth prospects relative to its tangible assets. Additionally, the price-to-sales ratio is 8.12 and the EV/EBITDA is -1.26, metrics that suggest investors are valuing the company based on revenue generation potential rather than current earnings power or cash flow generation. The stock has traded between a 52-week high of $1.40 and a 52-week low of $0.37, and while the exact current price is not listed in the provided facts, the valuation metrics suggest the market is pricing the asset significantly above the 52-week low, reflecting optimism about future commercialization despite the current lack of profits. The beta value of 2.27 indicates that the stock is highly volatile relative to the broader market, meaning it is expected to experience price swings that are more than twice as large as the overall market index.
Growth & Income
Revenue growth for the year over year is 46.2%, while earnings growth is N/A due to the company's current unprofitable status, implying that top-line expansion is occurring without a corresponding improvement in bottom-line performance at this stage of development. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% payout ratio, indicating that the firm reinvests all available resources and earnings back into research, development, and marketing to fuel future expansion rather than returning cash to shareholders. This reinvestment strategy is typical for commercial-stage medical device companies that prioritize accelerating product adoption and securing market share over immediate income distribution. Overall, the growth and income profile is characterized by rapid revenue expansion coupled with negative earnings and no current cash returns to shareholders, reflecting a high-risk, high-reward investment thesis centered on future commercial success.